- Home
- Publications
- Publication Search
- Publication Details
Title
SAR by kinetics for drug discovery in protein misfolding diseases
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume -, Issue -, Pages 201807884
Publisher
Proceedings of the National Academy of Sciences
Online
2018-09-27
DOI
10.1073/pnas.1807884115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers
- (2017) Giuliana Fusco et al. SCIENCE
- The Cellular Phase of Alzheimer’s Disease
- (2016) Bart De Strooper et al. CELL
- The amyloid hypothesis of Alzheimer's disease at 25 years
- (2016) Dennis J Selkoe et al. EMBO Molecular Medicine
- Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease
- (2016) Johnny Habchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation
- (2016) Paolo Arosio et al. Nature Communications
- An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A 42 aggregates linked with Alzheimers disease
- (2016) J. Habchi et al. Science Advances
- Dynamics of protein aggregation and oligomer formation governed by secondary nucleation
- (2015) Thomas C. T. Michaels et al. JOURNAL OF CHEMICAL PHYSICS
- A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers
- (2015) Samuel I A Cohen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers
- (2015) Samuel I A Cohen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- 2014 Alzheimer's disease facts and figures
- (2014) Alzheimers & Dementia
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- The amyloid state and its association with protein misfolding diseases
- (2014) Tuomas P. J. Knowles et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Chemical kinetics for drug discovery to combat protein aggregation diseases
- (2014) Paolo Arosio et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism
- (2013) S. I. A. Cohen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
- (2013) Zahra Hamrang et al. TRENDS IN BIOTECHNOLOGY
- The Amyloid State of Proteins in Human Diseases
- (2012) David Eisenberg et al. CELL
- Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils
- (2011) Jan Bieschke et al. Nature Chemical Biology
- Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift
- (2011) Todd E. Golde et al. NEURON
- Alzheimer's Disease: The Challenge of the Second Century
- (2011) D. M. Holtzman et al. Science Translational Medicine
- Protein aggregation diseases: pathogenicity and therapeutic perspectives
- (2010) Adriano Aguzzi et al. NATURE REVIEWS DRUG DISCOVERY
- Amyloid β-Protein Aggregation Produces Highly Reproducible Kinetic Data and Occurs by a Two-Phase Process
- (2009) Erik Hellstrand et al. ACS Chemical Neuroscience
- Development of Tau Aggregation Inhibitors for Alzheimer's Disease
- (2009) Bruno Bulic et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- An Analytical Solution to the Kinetics of Breakable Filament Assembly
- (2009) T. P. J. Knowles et al. SCIENCE
- PharmaGist: a webserver for ligand-based pharmacophore detection
- (2008) D. Schneidman-Duhovny et al. NUCLEIC ACIDS RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started